[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 832 Introduced in Senate (IS)]

<DOC>






119th CONGRESS
  1st Session
                                 S. 832

     To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
                  the Drug Price Negotiation Program.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             March 4, 2025

Mr. Tillis (for himself, Mr. Budd, Mrs. Blackburn, Mr. Daines, and Mr. 
   Lankford) introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL


 
     To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
                  the Drug Price Negotiation Program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Ensuring Pathways to Innovative 
Cures Act of 2025'' or the ``EPIC Act of 2025''.

SEC. 2. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND 
              BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION 
              PROGRAM.

    Section 1192(e)(1)(A)(ii) of the Social Security Act (42 U.S.C. 
1320f-1(e)(1)(A)(ii)) is amended--
            (1) by striking ``year, at least 7'' and inserting ``year--
                                    ``(I) for initial price 
                                applicability years 2026 and 2027, at 
                                least 7''; and
            (2) by adding at the end the following:
                                    ``(II) for initial price 
                                applicability year 2028 and each 
                                subsequent initial price applicability 
                                year, at least 11 years will have 
                                elapsed since the date of such 
                                approval; and''.
                                 <all>